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Am J Med Genet Part A 167A:11–25.Morquio A syndrome (mucopolysaccharidosis IVA) is a lyso-
somal storage disorder associated with skeletal and joint abnor-
malities and significant non-skeletal manifestations including
respiratory disease, spinal cord compression, cardiac disease,
impaired vision, hearing loss, and dental problems. The clinical
presentation, onset, severity and progression rate of clinical
manifestations of Morquio A syndrome vary widely between
patients. Because of the heterogeneous and progressive nature of
the disease, the management of patients with Morquio A syn-
drome is challenging and requires a multidisciplinary approach,
involving an array of specialists. The current paper presents
international guidelines for the evaluation, treatment and symp-
tom-based management of Morquio A syndrome. These guide-
lines were developed during two expert meetings by an
international panel of specialists in pediatrics, genetics, ortho-
pedics, pulmonology, cardiology, and anesthesia with extensive
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MorquioA syndrome (mucopolysaccharidosis [MPS] IVA,OMIM
#253000) is a lysosomal storage disorder (LSD) inherited in an
autosomal recessive fashion. It is caused by a deficiency in the
enzyme N-acetylgalactosamine-6-sulfatase (GALNS) due to a mu-
tation in the GALNS gene located on chromosome 16q24.3. This
deficiency results in accumulation of the glycosaminoglycans
(GAGs) chondroitin-6-sulfate and keratan sulfate (KS) in a variety
of tissues [Neufeld and Muenzer, 2001]. The disease is extremely
rare, with incidence rates ranging from 1 in 640,000 live births in
Western Australia to 1 in 76,000 live births in Northern Ireland
[Nelson, 1997; Nelson et al., 2003].
Infants with Morquio A syndrome usually appear normal at
birth. However, due to the accumulation of storage material in
tissues and organs, leading to cellular dysfunction, they progres-
sively develop profound skeletal and joint abnormalities and an
array of non-skeletal manifestations including respiratory disease,
spinal cord compression, cardiac disease, impaired vision, hearing
loss, dental problems, and to a lesser extent hepatomegaly [Mon-
tan˜o et al., 2007; Harmatz et al., 2013; Hendriksz et al., 2013a].
Morquio A can be distinguished from other types ofMPS disorders
by the typical short-trunk dwarfism with short neck (Fig. 1). The
skeletalmanifestations are generallymore extensive and severe than
in other types of MPS disorders. Hypermobility of joints is very
characteristic for Morquio A syndrome and distinguishes this
disease from other types of MPS. In contrast to most other types
of MPS disorders, Morquio A syndrome has not been associated
with cognitive impairment [Davison et al., 2013].
To date, over 220 mutations in the GALNS gene have been
identified [Morrone et al., 2014]. Themost commongenemutation
is present in <9% of the Morquio patients, giving rise to a wideFIG. 1. Typical appearance of patients with Morquio A syndrome, showing
abnormalities (left) and a patient with a non-classical phenotype of Morqheterogeneity with regard to clinical presentation, severity of
disease, and rate of progression [Tomatsu et al., 2011]. Whereas
most patients present with the classical phenotype, associated with
short stature and severe skeletal and joint abnormalities, some
patients do not have this characteristic appearance but may show
severe impairment in other domains such as cardiorespiratory
disease. The specific disease manifestations depend grossly on
the residualGALNSactivity and the accumulation rate and location
of storage material in tissues. Studies have shown similar clinical
manifestations in siblings with Morquio A syndrome, providing
some evidence for genotype-phenotype associations [Tylki-Szy-
man´ska et al., 1998; Rekka et al., 2012]. The accumulation of GAGs
throughout the body ultimately leads to premature death in most
instances,with a life expectancy ranging from10 to20 years of age to
almost normal in some patients [Tomatsu et al., 2011].
Because of the heterogeneous and progressive nature of the
disease, the management of patients with Morquio A syndrome
is challenging and requires a multidisciplinary approach. However,
due to the rarity of the disease, most clinicians are not familiar with
the special needs of these patients. Therefore, we developed inter-
national guidelines for the management and treatment of Morquio
A syndrome based on the outcome of two expert meetings.
On August 2–3, 2013, an international panel of 26 specialists in
pediatrics, genetics, orthopedics, pulmonology, cardiology, and
anesthetics with experience in Morquio A gathered in Amsterdam
for an expert meeting sponsored by BioMarin Pharmaceutical Inc.
During thismeeting, existing literature and clinical data on different
aspects of Morquio A syndrome were reviewed and discussed and
preliminary management and treatment guidelines were prepared.
These were discussed in more detail by a consensus panel of nine
experts during a secondmeeting in Barcelona on September 1, 2013.
Multiple observations in Morquio A resulted in the determinationshort stature with short neck and profound skeletal and joint
uio A syndrome showing normal stature (right).
TABLE I. Overview of Common Clinical Manifestations of Morquio A
Syndrome and Prevalence of These Manifestations in the MorCAP
Study (N¼ 325) at Baseline [Harmatz et al., 2013]
Musculoskeletal manifestations Prevalence
in MorCAP (%)
Short stature 93
Short neck 91
Spinal abnormalities
HENDRIKSZ ET AL. 13that patients cannot be classified into different subgroups based on
clinical presentation, severity of disease, and/or rate of progression.
These included the observed genotypic and phenotypic heterogene-
ity, the limited data on natural history and pathophysiology of the
disease and the observation that patients may show severe disease in
one domain, but not in another (e.g., severe respiratory disease, but
normal height). Because patients cannot be classified into different
subgroups, management differs depending on the clinical manifes-
tations of the patient.
Kyphoscoliosis 85
Odontoid dysplasia 65
Lumbar lordosis 56
Cervical spinal instability 49
Spinal disc disease 23
Hip dysplasia 71
Genu valgum (knock knees) 93
Pectus carinatum 97
Joint abnormalities
Laxity 87
Stiffness/pain 83
Contractures 52
Subluxation 47
Abnormal gait 94
Non-skeletal manifestations
Respiratory compromise (upper and lower
airway obstruction, respiratory restriction)
58
Cardiac abnormalities (valve disease, small
heart with low stroke volume and increased
heart rate)
43
Nervous system disorders (cervical myelopathy,
cervical/thoracolumbar cord compression)
51
Eye disorders 79
Corneal clouding 63
Visual impairment (20/80 or worse) 22
Ear/labyrinth disorders (most commonly hearing
impairment, otitis media)
77
Dental abnormalities 69
Abdominal abnormalities
Hepatomegaly 26
Splenomegaly 17
Other (e.g., hernias) 15DIAGNOSIS
Because of the progressive nature of Morquio A syndrome, early
diagnosis may be critical to optimize patient outcomes. Patients
with the disease generally gain clinical attention due to a cluster of
progressive, multisystemic clinical and/or radiographic findings
(Table I). Definitive diagnosis is facilitated by referral to a meta-
bolic/genetics center and is dependent upon clinical diagnostic
(radiographic imaging) and biochemical testing in a specialized
laboratory. Adiagnostic testing algorithm forMorquioA syndrome
has been published in 2013 (Fig. 2) [Wood et al., 2013]. Although
urinary GAG analysis and enzyme activity testing in a dried blood
spot (DBS) may raise suspicion of the presence of Morquio A, a
definite diagnosis usually entails demonstration of reducedGALNS
activity in leukocytes or fibroblasts. Molecular analysis can be
performed as a further confirmation of the diagnosis.
Obtaining a diagnosis of Morquio A remains a challenge due to
the rarity of the disease and similarities with other LSDs and
skeletal dysplasias. Specifically, patients that have been diagnosed
with, or are undergoing evaluation for spondyloepiphyseal dys-
plasia, pseudoachondroplasia, multiple epiphyseal dysplasia or
bilateral Legg-Calve´-Perthes disease should have Morquio A
excluded because of the similarities between these diseases and
Morquio A, unless there is a family history of any of these diseases
[Mendelsohn et al., 2013; Lachman et al., 2014]. Also, diagnosis of
Morquio A syndrome may be delayed in patients that do not
exhibit the classical initial signs of the disease such as kyphosis.
For example, patients with a more attenuated disease course may
first present with atypical signs such as hip stiffness and pain.
Furthermore, screening tests for Morquio A disease are subject to
false negative results. Total urinary GAG may not be elevated in
Morquio A patients, especially as patients grow older, because KS
levels decrease naturally with age and can reach levels consistent
with the upper range reported in unaffected individuals. More-
over, as not all Morquio A patients have elevated KS levels and as
KS may also be elevated in other disorders, KS measurements
should not be used as a diagnostic tool for Morquio A syndrome.
Therefore, it is optional to perform an enzyme activity assay in
DBS in addition to urinary GAG measurement in patients sus-
pected of having the disease. Noteworthy, the outcome of enzyme
activity testing in DBS depends on the stability of the enzyme and
the storage conditions of the sample [Camelier et al., 2011]. Based
on these considerations, it is recommended to proceed to enzyme
activity testing in leukocytes or fibroblasts not only when screen-
ing is positive or doubtful, but even when it is negative and the
clinical-radiological data are suggestive of Morquio A. In fact, if
there is strong clinical suspicion, an enzyme activity test could beperformed immediately, without prior urinary GAG or DBS
screening. When enzyme activity analysis in fibroblasts or leu-
kocytes is inconclusive, the test should be repeated and/or genetic
analysis should be performed. In these cases with inconclusive
enzyme results, identification of two known pathogenic muta-
tions on separate alleles is required for definitive diagnosis [Wood
et al., 2013]. Activity testing of other lysosomal enzymes (includ-
ing b-galactosidase and another sulfatase) in conjunction with
GALNS is recommended to rule out the presence of MPS IVB and
other enzyme deficiencies which could have GALNS secondary
deficiency, such as mucolipidosis II, III, MPS VI, and multiple
sulfatase deficiency [Wood et al., 2013]. Obtaining a correct
diagnosis is essential given the current availability of enzyme
replacement therapy (ERT) for Morquio A syndrome (see below).
FIG. 2. Diagnostic algorithm for Morquio A syndrome. Adapted from Wood TC et al. 2013 [Wood et al., 2013]. DBS: dried blood spot.
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Treatment Modalities to Provide the Deficient
Enzyme
Until recently, treatment of Morquio A syndrome was limited to
supportive, symptomatic care, including symptom-based medica-
tions, physical therapy, surgery, and rehabilitation. However, in
light of the pathophysiology of the disease, with a deficiency in a
single enzyme giving rise to an array of clinical manifestations, a
therapy that restores or replaces the deficient enzyme is desirable.
Current experience with hematopoietic stem cell transplantation
(HSCT), which has shown to be valuable in MPS IH (Hurler
syndrome), is very limited and not encouraging for patients
with Morquio A syndrome [Tomatsu et al., 2011; Algahim and
Almassi, 2013]. More data are required to provide evidence of its
efficacy in these patients.
ERT with recombinant human GALNS (elosulfase alfa) has
recently been approved for Morquio A syndrome, providing a
systemic treatment approach. Elosulfase alfa has shown to be effec-
tive with a favorable safety profile. A multicenter, phase 1/2, open-
label,dose-escalation study including20MorquioApatientsaged5–
18years showedsustained improvements in endurance, asmeasured
using a 6-min walk test (6MWT) and a 3-min stair climb test
(3MSCT), and respiratory function using elosulfase alfa 1.0mg/
kg/week and 2.0mg/kg/week, which persisted after approximately
2 years of treatment [Hendriksz et al., 2012]. Urinary KS also
decreased with treatment, with the largest decreases observed
when dosing at 2.0mg/kg/week. Based on the outcome of the phase
1/2 study, a multicenter, double-blind, placebo-controlled phase 3
study was performed to assess the efficacy and safety of infusionswith elosulfase alfa 2.0mg/kg every week and every other week
(N¼ 176; aged 5 years) [Hendriksz et al., 2014a]. The study
showed significant improvement in endurance of 22.5m in
6MWT distance during 24 weeks of treatment with elosulfase alfa
at 2.0mg/kg/week as compared with placebo (P¼ 0.0174). No
significant impact was observed with the every other week dosing
regimen. There was no significant effect of any of the dosing
regimens on the number of stairs climbed in a 3MSCT. Both dosing
regimens led to rapid and sustained reductions in urinary KS, with
the greatest effect seen with the weekly dosing regimen. The study
also showednumerical improvements over placebo after 24weeks of
treatment with elosulfase alfa 2.0mg/kg/week for most exploratory
endpoints, including maximum voluntary ventilation (MVV;
P¼ 0.094) and forced vital capacity (FVC; P¼ 0.304). A composite
measure developed by Delphi strategy based on an equal weighting
of the change from baseline to week 24 of the z-scores of three
componentmeasures, i.e., 6MWT, 3MSCT, andMVV, also showed
improvement. Both doses of elosulfase alfa had favorable safety
profiles, generally similar to that of other ERTs.Most adverse events
were mild or moderate infusion-associated reactions (IARs, occur-
ring after infusion onset andwithin 1 day after infusion end) such as
vomiting andpyrexia (fever),whichwere generallymanageablewith
symptomatic treatment and/or infusion rate modification. The
frequency of IARs was higher during the first 12 weeks of treatment
and tended to occur less frequently with time. As anaphylactic
reactions may occur during infusion, patients should be closely
observed during and after administration of elosulfase alfa.
Elosulfase alfa treatment should be implemented as soon as the
diagnosis of Morquio A syndrome has been confirmed to replace
the deficient GALNs enzyme. The recommended dose of elosulfase
HENDRIKSZ ET AL. 15alfa is 2.0mg/kg/week, administered intravenously over approxi-
mately 4 hr. The calculated dose should be diluted with saline to a
total volume of 100mL (patients weighing <25 kg) or 250mL
(patients weighing25 kg) at room temperature. Details of recon-
stitution may be found in the package insert. Supplementary
Appendix 1 provides instructions for the infusion of elosulfase
alfa. Elosulfase alfa should not be mixed with other infusions aside
from saline as compatibility with other products has not been
evaluated. Patients should be pre-treated approximately 30–60min
before each drug infusion with an antihistamine with or without
antipyretics. Patients with known risk factors for IARs may be pre-
treated with additional agents, such as H2 blockers, montelukast
sodium, or corticosteroids. Baseline and follow-up assessments
should be performed before and after starting ERT (see early
assessments).Multidisciplinary Approach
The diverse spectrum of disease manifestations of Morquio A
warrants a multi-disciplinary management approach, involving
an array of specialists coordinated by a physician experienced in
working with patients with LSDs. The role of this coordinating
physician, usually a pediatrician, metabolic physician, or clinical
geneticist, is to continuously monitor the evolution of disease, to
refer to a specialist as needed, to assist in coordinating the care/
recommendations from the multidisciplinary team, and to serve as
a medical home for the patient. In addition, this coordinating
physician needs to regularly educate other health professionals
(other specialists, dentists, and physiotherapists) about the disease
and discuss the risks and benefits of interventions and necessary
precautions with treatments/evaluations. The coordinating physi-
cian should provide guidance to the patient and family and
encourage correct follow-up of therapies [Martins et al., 2009].
In order to stimulate continuity of care, it is also important that
patients and families are educated about the disease and its possible
complications and risks.
It is important that the coordinating physician of Morquio A
patients organizes an experienced multidisciplinary team of spe-
cialists, concentrating all experience in a limited number of physi-
cians per subspecialty. This requires referral of a critical mass of
MPS patients to the same specialists, allowing them to accumulate
experience in treating these patients and encourage their education
on the disease.Early Assessments
Early recognition of clinicalmanifestations ofMorquioA syndrome
allows timely intervention and may help prevent irreversible dam-
age.Therefore,patientswithMorquioAsyndromeshouldundergoa
comprehensivemultisystemevaluationofphysicalmanifestationsof
disease, functional ability and disease burden at diagnosis. Table II
illustrates the recommended assessments organizedby organ system
along with a schedule for longitudinal assessment. Each patient
should also be referred to appropriate alliedhealthcare professionals
such as a physiotherapist, occupational therapist, and audiologist
depending on the disease burden at diagnosis.More details on these
assessments will be discussed below.SYMPTOM-BASED MANAGEMENT
Musculoskeletal Manifestations
Overview. Skeletal and joint abnormalities are the most ap-
parent and prevalent disease manifestations of Morquio A syn-
drome. The majority of patients show short stature with
corresponding short trunk and neck, abnormalities in spine, upper
extremities, thorax, hips and/or lower extremities, and joint and
gait abnormalities [Montan˜o et al., 2007; Aslam et al., 2013; Dha-
wale et al., 2013; Harmatz et al., 2013]. Radiographic findings
(dysostosis multiplex) suggesting Morquio A syndrome include
abnormally shaped vertebral bodies with anterior beaking, poste-
rior scalloping, platyspondyly and dens hypoplasia, thoracolumbar
kyphosis, short, broad metacarpals with proximal rounding, irreg-
ular carpal bones, rounded iliac wings, acetabular dysplasia, coxa
valga, genu valgum, ankle valgus, pectus carinatum, paddle-shaped
ribs and short, and thick clavicles (Fig. 3), although only some of
these may be present at diagnosis and missed by the non-expert
[Hendriksz et al., 2013b].
Typical features of Morquio A not occurring in other types of
MPS disorders are joint hypermobility and deformity in the wrists,
leading to floppy wrists with weak grip and loss of fine motor skills
[Aslam et al., 2013]. Patients may also show subluxation of the hip
joints and joint instability in the knees, which can exacerbate genu
valgum, patella dislocation, and gait abnormalities. Dens hypopla-
sia in combination with ligamentous laxity can lead to atlantoaxial
instability and subsequently to spinal canal stenosis and spinal cord
compression [Solanki et al., 2013].
Evaluation. Each Morquio A patient should be referred to an
orthopedic surgeon with experience treating MPS disease at diag-
nosis. Regular assessments of the hips, lower extremities, and spine
are recommended for optimal outcomes (Table II) [Solanki
et al., 2013; White et al., 2014]. Radiographic assessments of the
hips and lower extremities should focus on the presence of pro-
gressive hip dysplasia (shallow acetabulumwith subluxation), genu
valgum (tibiofemoral angle), and ankle valgus. Information on gait
and mobility can be obtained by a simple physical exam and
interrogation of patients. The clinical utility of gait analysis has
not been established at present.
Evaluation of the spine should focus on the presence of spinal
stenosis, instability and cord compression.Detailed instructions for
detecting spinal cord compression in patients with Morquio A and
indications for surgery have been recently published [Solanki
et al., 2013]. Briefly, plain radiography of the cervical spine (ante-
roposterior, lateral neutral, and flexion extension) and of the
thoracolumbar spine (anteroposterior and lateral) should be per-
formed every 1–3 years, depending on clinical history. Magnetic
resonance imaging (MRI) of the whole spine (neutral position)
should be done annually, focusing on all three potential sites of cord
compression, i.e., occipitocervical, cervicothoracic, and thoraco-
lumbar. If available, flexion-extension MRI of the cervical spine is
recommended every 1–3 years depending on signs, symptoms and
radiographic instability. Computed tomography (CT) of the spine
can be valuable for pre-operative planning.
Each patient with Morquio A syndrome also requires regular
assessment of upper limb function (fine motor skills). Valuable
standardized upper extremity function tests include evaluation of
TABLE II. Recommended Schedule of Assessments in Patients With Morquio A Syndrome
Assessment At diagnosis Follow-up frequency As clinically indicated Pre-ERTa
Medical history X Every visit
Physical examination X Every visit X
Upper limb function
Standardized upper extremity function test X Annually X
Hips and lower extremities
Hips/pelvis: AP pelvis radiograph X X
Lower extremities: standing AP radiographs X X
Spine/spinal cord compression
Plain radiograph spine X Every 1–3 years
MRI spine X Annually
CT neutral region of interest Xb
Cardiac function
ECGd X Every 1–3 yearsc Xb
Echocardiogram X Every 2–3 yearsc Xb
Heart rate X Annuallye
Respiratory function
FVC X Annuallyf X
MVV X Annuallyf X
Respiratory rate X Annuallye X
Oxygen saturationg X Annuallye
Overnight sleep study X Annuallyh
Neurological function
Neurological exam X Every visit (minimally every 6 months) X
Ophthalmological function
Slit-lamp biomicroscopy of cornea X X
Intraocular pressure X X
Refractive error X X
Examination of posterior segment X X
Scotopic and photopic electroretinogram X
Hearing
Audiology assessment (multimodal) X Annually
Dental evaluation
Evaluation of oral health by dentist X Annually
Endurance
6MWT, T25FWe X Annually Xi X
Growth
Height and length X Every visit X
Weight X Every visit X
Head circumference (3 years) X Every visit
Pubertal stage (age 9 until mature)j X Every visit X
Disease burden
Pain assessment X Every 6 months X
QoL questionnaire X Annually X
Functional testk/ADL questionnaire X Annually X
Evaluation by physiotherapist X Annually Xi
6MWT, 6-min walk test; ADL, activities of daily living; AP, anteroposterior; ECG, electrocardiogram; ERT, enzyme-replacement therapy; FVC, forced vital capacity; GAG, glycosaminoglycans; MRI, magnetic
resonance imaging; MVV, maximum voluntary ventilation; QoL, quality of life; T25FW, timed 25-foot walk.
aIf not done within 3-6 months, these assessments should be done before treatment with ERT is started.
bFor example pre-operative planning.
cECG and echocardiogram at diagnosis and after 1 year. If no signs of cardiac involvement, assessments can be repeated every 3 years, otherwise follow-up in expert centers according to standard of care.
dIn symptomatic patients (e.g., suspicious ECG) or post-pubertal patients, prolonged ECG (Holter monitoring for 5-7 days including normal exercising) should be done in expert centers at diagnosis and
every 1-3 years.
eHeart rate, respiratory rate, and oxygen saturation should bemeasured before and after each endurance test; choice of endurancemeasure depends on patient’s physical and developmental abilities (for
the 6MWT consistently use the same hallway).
fAnnual follow-up only required until children stop growing or when patient is on treatment. Once growth has stopped, testing frequency can be decreased to every 2-3 years provided that respiratory
symptoms remain unchanged.
gOxygen saturation can be determined either by pulse oximetry or by arterial blood gas analysis.
hScreening studies should be done in home on an annual basis. Full polysomnography should be performed at diagnosis in an expert center, then every 3 years, unless clinically indicated (or beforemajor
surgery). Patients with a positive test and those who need ventilatory support should be evaluated by a sleep expert.
iFor example pre- and post-operatively.
jPubertal stage can be assessed using two scores: genitalia (male), breast (female), pubic hair (male and female) as described by Marshall and Tanner [Marshall and Tanner, 1969, 1970].
kFor example 6MWT/T25FW, pinch/grip test and functional dexterity test.
FIG. 3. Typical radiographic features (dysostosis multiplex) in patients with Morquio A syndrome: (A) Rib cage from a 12 year-old female
Morquio A patient showing paddle shaped ribs. (B) Typical dysostosis multiplex changes in the pelvis and hips of an 8 year-old Morquio A
patient showing dysplastic femoral epiphyses and narrowed inferior ilia sloping into the acetabular roofs. (C) Knee valgus in a 7 year-old
Morquio A patient. Reproduced from Dhawale et al. [Dhawale et al., 2012] with permission from Lippincott Williams & Wilkins. (D) Cervical
spine showing dens hypoplasia, which may be associated with atlantoaxial instability. Reproduced from Solanki et al. [Solanki et al., 2013]
with permission from Springer. (E) Thoracolumbar spine changes including platyspondyly, anterior beaking, thoracolumbar kyphosis, and
posterior vertebral scalloping. Reproduced from Solanki et al. [Solanki et al., 2013] with permission from Springer.
HENDRIKSZ ET AL. 17grip strength and pinch strength, the 9-hole peg test and the
functional dexterity test [Aaron and Jansen, 2003; Poole
et al., 2005]. In order to obtain consistent measurements, it is
important to record the position of the wrist and whether the wrist
was supported or not during testing. Passive and active assessments
of the range of motion of elbows and shoulders can be useful, but
generally do not have therapeutic consequences.
Interventions. Interventions for managing hip subluxation,
knee valgus, and ankle valgus in patients withMorquioA syndrome
have been recently discussed in detail byWhite et al. [2014]. Briefly,
depending on age and severity of the deformity, hip subluxation can
be managed using pelvic and femoral osteotomy, shelf acetabulo-
plasty, or total hip arthroplasty [Tassinari et al., 2008; Pryce Lewis
andGibson, 2010;Dhawale et al., 2012;White, 2012]. Correction of
knee valgus using guided growth (8-plate hemiepiphysiodesis) iseffective in the growing child and may prevent hip problems and
ankle valgus at a later age [Dhawale et al., 2012]. Knee osteotomy or
knee arthroplasty can be an option for older patients [Atinga and
Hamer, 2008]. Ankle valgus can generally bemanaged by orthotics,
butmay sometimes require surgical correction (e.g., guided growth
orosteotomy) [Dhawale et al., 2012].Recurrence of the knee and/or
ankle valgus is not uncommon.
Interventions for spinal cord compression in patients with Mor-
quio A syndrome include spinal decompression, fusion or a combi-
nation of both [Ransford et al., 1996; White, 2012; Solanki
et al., 2013]. Different approaches for managing spinal cord com-
pression at the axial, subaxial, and thoracolumbar spine and the
associated risks have been discussed by Solanki et al. [Solanki
et al., 2013]. It is important to be aware that instability and stenosis
may develop again in the region of previous fusion after surgery
18 AMERICAN JOURNAL OF MEDICAL GENETICS PART A[Dede et al., 2013]. Surgical interventions requiring anesthesia
warrant pre-operative evaluation of anesthetic risk factors and
should be performed by a team experienced in managing these
cases. Peri-operative care and anesthesia is discussed in more detail
below.
Physical therapy and pain medication can be beneficial to
manage musculoskeletal manifestations in some patients. A walk-
ing aidorwheelchair canhelp improvemobility andpain.However,
efforts should be made to keep patients independently mobile as
long as possible as the quality of life (QoL) drops dramatically when
patients become wheelchair dependent [Hendriksz et al., 2014b].Respiratory Manifestations
Overview. Respiratory impairment is the leading cause of
morbidity and mortality in patients with Morquio A syndrome
and can be due to obstructive or restrictive disease [Montan˜oFIG. 4. GAG deposits within walls of the upper airway of a
patient with Morquio A causing narrowing of the pharynx and
larynx.et al., 2007; Berger et al., 2012]. The upper and lower airways of
Morquio A patients can be narrowed and tortuous due to a
combination of GAG deposition in airway walls (Fig. 4), abnor-
malities in the skull or spine, tracheal distortion, tracheobrochno-
malacia, and thickened secretions. Patients may develop airway
occlusionuponneckflexion andadopt a “sniff position” topreserve
airway patency. Restrictive disease can develop due to a small and
abnormally shaped thoracic cage or impaired diaphragmatic mo-
tility [Berger et al., 2012]. An early sign of respiratory impairment is
sleep disordered breathing (SDB), i.e., obstructive sleep apnea
(OSA) or sustained hypoventilation. Over time, SDB can have
cardiovascular consequences, such as pulmonary hypertension,
with consecutive development of cor pulmunale, and can lead to
cardio-respiratory failure.
Evaluation. Forced vital capacity (FVC) and maximum vol-
untary ventilation (MVV) should be assessed annually until chil-
dren stop growing. Once growth has stopped, the frequency of
testing canbe decreased to every 2–3 years provided that respiratory
symptoms remain unchanged. Additional testing should be per-
formed if respiratory symptoms change or if intercurrent illnesses
occur. In addition, evaluation before and after initiation of ERT is
recommended. Because of the growth impairment associated with
Morquio A, expressing FVC andMVV as % of normal is of limited
value. However, absolute values can be used tomonitor respiratory
function in patients over time.
In order to detect reduced exercise capacity due to respiratory
restriction, it is also recommended to measure respiratory rate and
arterial oxygen saturationbefore andafter annual endurance testing
(e.g., utilizing the 6MWT).Oxygen saturation can be obtainedwith
a pulse oximeter along with heart rate. Reduction in oxygen
saturation during exercise should prompt additional evaluation
(e.g., pulmonary function and chest radiograph). Treatment tar-
geted to the etiology for the desaturation may be administered and
use of supplemental oxygen can be considered particularly if the
oxygen saturation falls below 88–90%. In addition, the presence of
inordinate tachycardia during exercise should prompt cardiac
evaluation (e.g., assessment of valve and myocardial function
and assessment for cardiac arrhythmia).
Routine physical exam can also identify signs of potential
respiratory problems such as an enlarged tongue or sniff position.
Fiber-optic laryngoscopy may be considered in patients showing
obstructive symptoms and prior to surgery. Evaluation of respira-
tory function is also recommended before any planned air travel to
ensure safety during the flight [Ahmedzai et al., 2011; Shrikrishna
and Coker, 2011].
In order to timely detect SDB, in-home screening sleep studies
that monitor oxygen saturation are recommended on an annual
basis. A sleep studywith full polysomnography in an expert center is
recommended at diagnosis and then every 3 years, unless clinically
indicated or before major surgery. Patients with a positive test and
those who need ventilatory support should be evaluated by a sleep
expert.
Interventions. The management of respiratory manifesta-
tions in patients with MPS has been discussed by Berger et al.
[Berger et al., 2012]. Briefly, patients may benefit from support-
ive therapies such as regular influenza and pneumococcus vac-
cinations, bronchodilators and aggressive and prompt treatment
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my and/or adenoidectomy are frequently required in patients
with obstructed upper airways. SDB can generally be managed
successfully by continuous positive airway pressure (CPAP, for
patients with OSA) or non-invasive ventilator support (e.g.,
bilevel positive airway pressure to treat sustained hypoventila-
tion). Tracheostomy may be required if ventilator support is
ineffective or in patients with airway obstruction during wake-
fulness. However, as many complications may occur during and
after tracheostomy placement, this procedure should be per-
formed only in centers with experience in Morquio A disease
[Berger et al., 2012].Cardiovascular Manifestations
Overview. Unlike other MPS disorders [Braunlin et al., 2011],
cardiac valve abnormalities inMorquioApatients are generally very
mild. Occasionally, older patientsmay develop clinically important
cardiac disease post-pubertally. Detailed evaluation of cardiac data
performed inMorquioApatients enrolled in themulticenter, cross-
sectional Morquio A Clinical Assessment Program (MorCAP)
[Harmatz et al., 2013] demonstrated variable incidence of valvular
regurgitation and stenosis. In addition, Morquio A patients typi-
cally have a small left ventricular diameter and an abnormally low
stroke volume (personal communicationProf.Dr. C.Kampmann).
As compensation, these patients may demonstrate an abnormally
high heart rate and highmyocardial work index. In addition, blood
pressure in these patients can increase dramatically if they switch
from a supine to a sitting position.
Evaluation. Because cardiac pathology inMorquioApatients
is generally mild, electrocardiography (ECG) and echocardiog-
raphy every 3 years are sufficient, if there are no signs of cardiac
involvement (Table II). Heart rate and blood pressure should be
measured before and after annual endurance testing. Resting
blood pressure and heart rate (before endurance testing) can
indicate presence of arterial hypertension or resting tachycardia.
Repeat measurement directly after endurance testing provides
insight into a patient’s cardiovascular reserve and might detect
cardiovascular incompetence. The left ventricular diameter gen-
erally does not increase after cessation of growth unless significant
valve disease is present. In symptomatic patients (e.g., suspicious
ECG) or post-pubertal patients, prolonged ECG (Holter moni-
toring for 5–7 days including normal exercising) should be
performed at diagnosis and every 1–3 years to detect cardiac
arrhythmias, which may be suspected based on experience in
other MPS types.
Interventions. It is important to be aware that an elevated
heart rate in Morquio A patients may be needed to compensate
for a small cardiac stroke volume. Therefore, treatment of
tachycardia with beta blockers should be avoided. Also ACE
inhibitors should be used with caution as they may result in a
disproportional increase in heart rate, especially in subjects with
marked changes in blood pressure between supine and sitting
positions.
Valve replacement may be considered for patients that present
with or progress to severe aortic or mitral valve disease [Nicolini
et al., 2008; Pagel and Almassi, 2009].Neurological Manifestations
Overview. MorquioApatients candevelopneurological symp-
toms due to myelopathy secondary to spinal cord compression
[Harmatz et al., 2013; Solanki et al., 2013]. The MorCAP baseline
data (N¼ 325) showed nervous system disorders or cord compres-
sion in 51% of patients, including 30% with cervical myelopathy,
14%with cervical cord compression, and 13%with thoracolumbar
cord compression [Harmatz et al., 2013]. The prevalence of these
disorders increasedwith age, i.e., 36% in 0–4 year old patients, 48%
in the 5–11 year olds, 58% in 12–18 year olds, and 55% in>18 year
olds. Cervical cord compression can lead to unsteady gait, upper
and lower extremity weakness, dysesthesias, urinary dysfunction,
paralysis and sudden death [Lipson, 1977; White, 2012]. At the
thoracolumbar level, cord compression may result in lower back
pain, radiating leg pain and paraplegia with insidious onset and
associated consequences such as lower limb weakness, sensory
anomalies and disturbed bladder function [Dalvie et al., 2001].
Evaluation. In order to identify patients with spinal cord
compression in an early stage, neurological examinations at maxi-
mum intervals of six months are recommended (Table II). A
neurological examination in patients with Morquio A syndrome
may reveal hyperreflexia, increased muscle tone, pyramidal tract
signs (ankle clonus and Babinski sign) and/or proprioceptive
deficits [Solanki et al., 2013]. However, neurological assessment
can sometimes be difficult due to lower limb function involvement.
Also, neurological signs and symptoms may underestimate the
severity of spinal cord compression seen on MRI. Clinical and
neurological findings should therefore be correlated with imaging
studies of the spine [Solanki et al., 2013]. In patients with multi-
segmental myelopathy, it can be difficult to determine the level of
compression responsible for the observed neurological deficit. If
available, it can be worthwhile to measure somatosensory evoked
potentials (SEPPs) and motor evoked potentials (MEPs) on an
outpatient basis. However, the value of these studies in the evalua-
tionof spinal cord compression still needs tobe established [Solanki
et al., 2013].
Interventions. MRImay over or underestimate the risk of cord
compression in patients with Morquio A syndrome, therefore a
neurosurgeon should be part of themultidisciplinary team to assist
with making this assessment. Neurological monitoring during
surgical interventions requiring anesthesia is recommended in
cases where spinal cord compression is a concern. The treatment
of spinal cord compression has been discussed previously (see
musculoskeletal manifestations).
Ophthalmological Manifestations
Overview. Diffuse corneal clouding and refractive error prob-
lems (astigmatism, myopia, and hyperopia) are very common
findings in Morquio A patients and may lead to reduced visual
acuity and photosensitivity [Couprie et al., 2010; Summers and
Ashworth, 2011; Harmatz et al., 2013; Hendriksz et al., 2013a].
Although corneal clouding worsens with age, it tends to be less
severe in Morquio A syndrome than in MPS I and MPS VI [Ash-
worth et al., 2006]. Cataract, open-angle glaucoma, retinopathy,
optic disc swelling and optic nerve atrophy, and pseudoexoph-
thalmos due to shallow orbits have also been reported sporadically
20 AMERICAN JOURNAL OF MEDICAL GENETICS PART Ain patients with Morquio A syndrome [Dangel and Tsou, 1985;
Cahane et al., 1990; Iwamoto et al., 1990; Olsen et al., 1993;
Ka¨smann-Kellner et al., 1999; Ashworth et al., 2010; Couprie
et al., 2010; Hendriksz et al., 2013a].
Evaluation. Ophthalmological function should be assessed in
each Morquio A patient at diagnosis (Table II) [Fahnehjelm
et al., 2012; Hendriksz et al., 2013a]. Afterwards, a basic evaluation
of vision/ocular abnormalities should be part of the general
physical examination that is recommended at every visit. Referral
to an ophthalmologist is only required in case of clinical
abnormalities.
Interventions. Patients with impaired vision may benefit from
refractive correction or low vision aids; filtering glasses and hats can
be used tomanage photosensitivity [Tomatsu et al., 2011]. Corneal
clouding can be managed surgically by corneal transplantation
[Leslie et al., 2005; Tomatsu et al., 2011], but reopacification of
corneal grafts may occur similar to experience in other MPS
disorders [Ka¨smann-Kellner et al., 1999]. Concomitant retinopa-
thy, glaucoma, or optic nerve atrophy can also limit restoration of
vision with corneal transplantation. Patients with cataracts may
benefit from cataract surgery.Audiological Manifestations
Overview. Sensorineural ormixed conductive and sensorineu-
ral hearing loss commonly develop in inMorquio A patients in the
first decade of life [Bredenkamp et al., 1992; Riedner and
Levin, 1977]. Hearing loss may result from recurrent respiratory
tract infections or otitis media, deformity of the ossicles, and/or
abnormalities of the inner ear [Bredenkamp et al., 1992; Riedner
and Levin, 1977; Tomatsu et al., 2011; Hendriksz et al., 2013a]. A
study including 18 patients with Morquio A syndrome showed
conductive hearing loss in all three patients<8 years and mixed or
sensorineural hearing loss in 14out of 15patients8 years [Riedner
and Levin., 1977]. Ten patients required a hearing aid. In the
MorCAP study, ear and labyrinth disorders (mostly hearing im-
pairment and otitis media) were reported by 77% of patients
[Harmatz et al., 2013].
Evaluation. Hearing impairment is an underestimated issue in
Morquio A patients. Therefore, age-adjusted audiology assess-
ments should be done at diagnosis and on an annual basis thereafter
(Table II) (e.g., acoustic emissions in neonates, visual reinforce-
ment audiometry in children from 8 months up to 3 years of age,
conventional ear checks for patients of 3 years or older) [Hendriksz
et al., 2013a].
Interventions. Conductive hearing loss due to retainedmiddle
ear fluid can be treated using ventilation tubes [Hendriksz et al.,
2013a]. Long-lasting types of tympanostomy tubes are preferable to
use on the first occasion considering the anesthetic risks and the risk
of the reoccurrence of themiddle ear fluid [Hendriksz et al., 2013a].
Post-aural hearing aids may be most appropriate if a progressive
neurosensory element to hearing loss is present.FIG. 5. Pediatric (top) and adult (bottom) teeth of patients with
Morquio A showing widely spaced teeth, pointed cusps and
spade-shaped incisors.
Abdominal Manifestations
Overview. Abdominal manifestations of Morquio A include
umbilical, inguinal or bilateral diaphragmatic hernias, hepatomeg-aly, splenomegaly (less common), and other gastro-intestinal dis-
orders (e.g., chronic constipation, diarrhea) [Nursal et al., 2000;
Harmatz et al., 2013; Hendriksz et al., 2013a]. However, gastro-
intestinal manifestations tend to be less prominent than in other
types of MPS disorders.
Evaluation. Assessment of gastro-intestinal problems inMor-
quio A patients should be part of routine clinical evaluation.
Interventions. Hernias can be surgically repaired by hernior-
raphy and frequently recur.Dental Abnormalities
Overview. Patients with Morquio A syndrome tend to have
small,widely spaced teeth, oftenwith thin, structurallyweak enamel
and small pointed cusps, spade-shaped incisors, pitted buccal
surfaces, and other developmental abnormalities of primary and
permanent dentition (Fig. 5) [Kinirons and Nelson, 1990; Rølling
et al., 1999; James et al., 2012]. Therefore, they are vulnerable to
caries formation [James et al., 2012].
Evaluation. Patients should be referred to a dentist at diagno-
sis. Closemonitoring of dental development (at least annually) and
regular dental care is important to prevent caries and attrition of the
teeth [Tomatsu et al., 2011; Hendriksz et al., 2013a].
Interventions. In order to prevent caries, Morquio A patients
should receive fluoride supplementation; fissure sealing of denti-
tion may be considered in some cases.
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Endurance. Patients with Morquio A syndrome may show
reduced endurance due to impaired cardiac, respiratory, musculo-
skeletal, and/or neurological function, which may impact signifi-
cantly on functional status/mobility and QoL [Harmatz et al.,
2013]. Endurance testing at diagnosis and annually thereafter is
recommended to follow up overall disease progression (Table II).
Information on endurance can be obtained by routinely asking
endurance questions during clinical exam (e.g., How far can you
walk? How many stairs can you climb?) or by using an endurance
test.
The 6-minwalk test (6MWT) is considered themost appropriate
endurance test for patients with Morquio A syndrome, as it is
readily available and is a combined assessment of musculoskeletal
and cardiopulmonary capacity. This standardized test measures
how far a person can walk on a hard, flat surface in 6min and
has been used to assess endurance in several MPS (including
Morquio A) clinical trials [American Thoracic Society, 2002;
Wraith et al., 2004; Harmatz et al., 2005; Harmatz et al., 2006;
Muenzer et al., 2006; Hendriksz et al., 2012]. Detailed instructions
for the 6MWT have been published by the American Thoracic
Society [American Thoracic Society, 2002]. In order to allow
comparison of test outcomes, the 6MWT should always be per-
formed at the same location. Walking aids used during the 6MWT
should be documented and should be consistent over time (i.e., do
not change type of aid or perform with/without aid over time). In
patients with limited ambulation who are unable to do the 6MWT,
endurance canbe assessedusing a timed25-footwalk test (T25FW).
TheT25FW,whichhasoriginally beendevelopedas a componentof
theMultiple Sclerosis FunctionalComposite (MSFC),measures the
time needed to cover 25 feet [Polman and Rudick, 2010]. For
Morquio A patients, the test has been adapted in order to allow
patients to cover the 25 feet distance by crawlingor rolling ifwalking
is impossible. Detailed instructions for the T25FW for Morquio A
patients, based on the instructions developed for multiple sclerosis
patients, are given in Supplementary Appendix 2. Blood saturation,
heart rate and respiratory rate should be measured immediately
before each endurance test, upon test completion, and 2min after
test completion. Compromised vision and hearing should be taken
into consideration when implementing these tests in Morquio A
patients. Endurance testing is also recommended before and regu-
larly after initiation of ERT as a measure of treatment efficacy.
Growth. The majority of adult patients with Morquio A syn-
drome are below the 3rd centile in height on the Center for Disease
Control growth charts and shorter than 120 cm [Harmatz
et al., 2013]. They also tend to have a higher body mass index
than normal (>85th centile) [Montan˜o et al., 2008]. Growth
velocity generally starts to fall below normal levels after the age
of 1 year [Montan˜o et al., 2008]. Growth charts for patients with
Morquio A syndrome have been published in 2008 [Montan˜o
et al., 2008].
Standing height (sitting height if the patient is unable to stand),
length (supine) and weight, head circumference (up to 3 years of
age), and stage of puberty (from age 9 years until maturity)
[Marshall and Tanner, 1969, 1970] should be documented at
diagnosis and at each visit to follow the relative change in individu-als over time (Table II). Height andweight should also bemeasured
before and regularly after initiation of ERT to evaluate the impact of
treatment. One should be aware that height may vary (and even
decrease) over time due to skeletal changes such as kyphosis or knee
valgus. Because obesity may exacerbate lower limb and other
problems, it is important to monitor weight (prevent excessive
increase inBMI) inpatientswithMorquioA syndrome.Assessment
of bonedensity is difficult to interpret inMPSpatients given the lack
of appropriate normative data for comparisons, and therefore not
recommended on a routine basis [Fung et al., 2010].
Pain. Pain is a major, but underreported, symptom of Mor-
quio A syndrome [Harmatz et al., 2013]. It is mainly related to
musculoskeletal problems (e.g., joint pain and muscular pain) and
may occur in many parts of the body, including the spinal area,
upper and lower extremities, and the head and neck area. A patient-
reported outcomes study in 27 adults and 36 children/adolescents
with Morquio A showed that pain can interfere profoundly with
activities of daily living (ADL) and canbe adriver forwheelchair use
[Hendriksz et al., 2014b]. Although increased mobility (less fre-
quent wheelchair use) was found to be associated with more severe
andwidespreadpain, pain interferencewithADLwasmost severe in
patients using a wheelchair all the time.
Pain severity should be assessed at each clinical visit by specifi-
cally asking patients about their analgesic use, or about recent
improvement or worsening of pain (Table II). A simple, self-
completed question for rating pain/discomfort is included in the
EQ5D-5L (www.euroqol.org). This standardized questionnaire is
developed to measure health-related QoL in a wide range of health
conditions and currently available in 106 languages. External
factors and conditions should be considered when interpreting
pain assessment, for example pain might be increased after a long
flight.
Quality of Life. Many factors may affect QoL in Morquio A
patients, including reduced endurance or mobility, difficulties in
ADL, dependence on caregivers, frequent surgical interventions,
pain and fatigue [Harmatz et al., 2013; Hendriksz et al., 2013a]. It is
important to be aware that although patients using a wheelchair all
of the time experience less pain severity and fatigue due to limited
functional activity, they tend to have a considerably poorerHRQoL
[Hendriksz et al., 2014b]. Regular assessments of QoL and ADL are
recommended (Table II). QoL can be assessed using reproducible
and age-appropriate questionnaires such as the EQ-5D-5L. There is
need for QoL questionnaires for adult patients, covering adult-
specific needs such as employment, financial problems, and sexu-
ality and reproduction. Information on the disease impact on ADL
can be obtained using previously discussed functional tests (e.g.,
6MWT/T25FW, pinch/grip test and functional dexterity test),
open-ended questions, and reproducible, age-appropriate ADL
questionnaires such as the MPS Health Assessment Questionnaire
(MPS HAQ) [Harmatz et al., 2013].
Simple interventions may considerably improve the functional
capacity andQoLof patientswithMorquioA syndrome. For school
children, communication between school staff, physiotherapists
and health professionals about the inclusion of the patient in
activities at school, specialized equipment, and walking aids is of
major importance. It may be valuable to educate schools, including
teachers and peers, on the disease and the fact that children may be
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enhance understanding, stop the potential for bullying, and stimu-
late peer tolerance and respect. When mobility is decreasing,
adequate advice can be valuable for the patient in order to achieve
a good balance between independence and maintaining mobility.
Regular assessmentof vision andhearing is important to ensure that
deficits in these areas are being addressed.
Urinary GAG. In the absence of a well validated, readily
available KS assay, measurement of urinary KS has a very limited
role in the diagnosis of Morquio A patients and, while it is a robust
marker of pharmacodynamic activity of elosulfase alfa, its clinical
utility as a surrogate marker for elosulfase alfa efficacy has not been
established. In the phase III study, urinary KS demonstrated a
pharmacodynamic effect of elosulfase alfa in the weekly 2mg/kg
study population resulting in a 41% decrease in urinary KS at
week 24 of the study [Hendriksz et al., 2014a]. However, changes in
urinaryKSdid not correlatewith clinical efficacymeasures.Urinary
KS can bemeasured prior to and just after starting elosulfase alfa to
determine the pharmacodynamic effects of ERT treatment. Annual
follow-upassessments areof limiteduse. Furthermore, the standard
dye-based quantitative total GAG tests are predicted to be even less
sensitive than the urinary KS test, and there is no current data to
suggest that this testing is of any use in clinical management of
Morquio A [Wood et al., 2013].Peri-Operative Care and Anesthesia
Patients with Morquio A syndrome may be at high anesthetic risk
due to cervical instability, compromised respiratory function or
cardiac problems [Theroux et al., 2012Walker et al., 2013]. There-
fore, any elective surgery requires pre-operative evaluation of
anesthetic risk factors and should be performed by an experienced
team at centers familiar with MPS disorders. A spectrum of airway
management equipment should be available during and after the
procedure. The anesthetic problems and detailed instructions for
pre-, peri- and post-operative care of patients with MPS in general
and for patientswithMorquioAhavebeenpublished in 2013 in two
papers by Walker et al and Theroux et al. [Theroux et al., 2012;
Walker et al., 2013].Physiotherapy
As mentioned previously, Morquio A patients require regular
evaluation of upper limb function by for example a physiotherapist.
Referral to a physiotherapist on a routine basis (Table II) can also be
valuable to encourage patients to perform routine exercises to
better preserve joint function and fine motor skills [Tomatsu
et al., 2011] and to participate in activities such as swimming or
hippotherapy (occupational and physical therapy using the move-
ments of a horse). Physiotherapy can be personalized to each
patient and directed to address those joints and/or functions
that are most impacted for that individual at that time.Transition From Pediatric to Adult Care
During late adolescence, the relationship of patients withMorquioA
syndrome with the medical team changes from a passive (with theparents mostly communicating with the medical team) to an active
one (i.e., direct communication between patient and healthcare
provider) [Hendriksz, 2013c]. This process, during which patients
become increasingly independent from their parents and start man-
aging their own health care, can be difficult, particularly in countries
where the organization and facilities of the healthcare system require
transition from pediatric to adult services. In order to guide this
process and to ensure that the adult providers are knowledgeable in
managing these patients and that patients are not lost to follow-up,
there is need for a formal, site-specific, transition strategy. For
example, joint visits with the pediatrician and the physician coordi-
nating theadultpatient fora fewyearsor inputofpatient information
by the pediatrician into a registry accessible for the adult team may
guide adult care after transition. Alternatively, patients may carry
their own health records. In any case, it is important to involve the
patient and his/her family in this transition process.FUTURE DIRECTIONS
Insights into the natural history and pathophysiology ofMorquioA
syndrome have grown rapidly over the past decade thanks to large
observational studies, mutation analyses, and basic research in
the framework of the development of ERT [Tomatsu et al., 2005;
Montan˜o et al., 2007; Tomatsu et al., 2008; Harmatz et al., 2013].
Nevertheless, current knowledge on the disease remains relatively
limited. Future studies providing additional insight into genotypic-
phenotypic correlations and biomarkers for disease activity are
warranted and may allow the development of individualized man-
agement strategies according to the clinical manifestations of a
patient.
As for other types of MPS disorders, implementations in symp-
tommanagement and the recent introduction of ERT forMorquio
A syndromemay create new challenges for the future management
of these patients. AsERTcanhave apositive impact onmobility and
endurance, it may encourage patients to adopt a more active life
style. Thismay also create new expectations for the future and lower
the threshold for orthopedic surgery. If the life expectancy of
patients increases due to better treatment options, the previous-
ly-discussed needs of adult patients will gain even greater impor-
tance. A longer life expectancy is likely to be associated with an
increase in the number of surgical interventions in patients with
MorquioA andwith increasing anesthetic challengeswhen patients
grow older.
Another challenge for the future will be improving the conve-
nience of ERT. Weekly visits to the hospital for infusions can be
perceived as very bothersome by patients and families, especially if
they have to travel far. Creating the opportunity for remote/home
infusions may provide an answer to this problem.ACKNOWLEDGMENTS
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